Mabpharm (HKG:2181) shrank its attributable loss in 2024 by 39% to 127.9 million yuan from the 209.4 million yuan loss in the year-ago period, a Wednesday filing with the Hong Kong bourse said.
Loss per share stood at 0.03 yuan, compared with 0.05 yuan loss per share in 2023.
The biopharmaceutical firm's revenue for the year increased by 196% to 258.2 million yuan from 87.2 million yuan a year prior.
The higher revenue was mainly due to the launch of CMAB009 in the market, higher sales of CMAB007 and CMAB008, and a boost in revenue from the exclusive right for commercialization and contract development and manufacturing agreement of CMAB806.
The firm attributed the shrinking of loss mainly to an increase in gross profit, as well as lower research and development expenses.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
No relevant data is available